SALT LAKE CITY, Aug. 31, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that its Board of Directors has authorized the repurchase of an additional $100 million of the Company’s outstanding common stock, following the completion of its previously authorized stock repurchase program initiated in May 2010.
